Evidence map›Paper›PMID 29177121›Full record

ArticleExpert opinion on orphan drugs2017

Hard targets for a second skeleton: therapeutic horizons for fibrodysplasia ossificans progressiva (FOP).

Frederick S Kaplan, Robert J Pignolo, Mona M Al Mukaddam, Eileen M Shore

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Expert opinion on orphan drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Review
  3. Clearance of Senescent Cells From Injured Muscle Abrogates Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Frederick S KaplanIsaac & Rose Nassau Professor of Orthopaedic Molecular Medicine; Professor of Orthopaedic Surgery and Medicine, Co-Director, Center for Research in FOP and Related Disorders, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Robert J PignoloRobert and Arlene Kogod Professor of Geriatric Medicine; Chair, Division of Geriatric Medicine & Gerontology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Mona M Al MukaddamAssistant Professor of Medicine in the Division of Endocrinology, Diabetes and Metabolism; Ian Cali Clinical Scholar, Center for Research in FOP and Related Disorders, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Eileen M ShoreCali-Weldon Professor of FOP Research; Professor of Orthopaedic Surgery and Genetics, Co-Director, Center for Research in FOP and Related Disorders, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

Funding

The Cellular and Molecular Basis of FOP LesionsR01AR041916 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI KAPLAN, FREDERICK SAMUEL, SHORE, EILEEN M · 1994 to 2014
$3.8M
NIAMS NIH HHS R01 AR041916
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Activin AACVR1bone morphogenetic protein receptorsfibrodysplasia ossificans progressivaheterotopic endochondral ossificationhypoxia

Identifiers

PMID29177121
PMCPMC5697787

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.